Menu
SOPHiA GENETICS™ thrilled to be back at ASCO 2025! Meet our experts at booth #32131 to hear about our biopharma solutions.Learn how we are leveraging our unique AI expertise, to provide an unparalleled offering, unlocking insights from complex data types, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines
SOPHiA GENETICS™ thrilled to be back at AACR 2025! Visit us at booth #2856 to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions. By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
SOPHiA GENETICS™ thrilled Charité Mayo Conference 2025! Visit us to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions.
We’re back at World Clinical Biomarkers & CDx Boston!
Join us to explore how you can harness the power of decentralization to drive global health equity.
With our universal, scalable and technology-agnostic platform now serving 750 customers across 72 countries, coupled with our expertise in developing and deploying decentralized genomic applications, we help you enhance patient and market access to relevant genomic information, and match patients to the right trials and treatments.
Development of an NGS-based ecDNA detection solution into a clinical trial device targeting oncogene amplification
September 5, 2024 | 03:10 to 03:40 PM | Track A
SPEAKERS
Julien Pontis, PhD
Technical Product Manager and Lead Scientist, SOPHiA GENETICS
Peter Krein, PhD
Vice President of Precision Medicine, Boundless Bio
David Lu, PhD
Director of Precision Medicine, Boundless Bio
It’s well established that patients with oncogene amplification generally do not benefit from standard-of-care cancer treatments and extrachromosomal DNA (ecDNA) has emerged as a unique biology of cancerous tumors.
Join us in this talk to hear about the Boundless Bio and SOPHiA GENETICS’s partnership on the development and validation of a prototype device for use in ecDNA-directed therapies.
Hear how the integration of ecDNA technology will impact the journey of patients with oncogene-amplified cancers.
Delve into the development and validation path to transform access to innovative precision therapies.
Learn about SOPHiA GENETICS’ unique ability to harmonize data derived from diverse genomic instruments and deploy as a robust, standardized solution enabling a decentralized model for clinical trial testing.
[et_pb_section admin_label="section"] [et_pb_row admin_label="row"] [et_pb_column type="4_4"][et_pb_text admin_label="Text"][/et_pb_text][/et_pb_column] [/et_pb_row] [/et_pb_section]SOPHiA GENETICS is excited to be a part of the BioData World Congress 2022 annual meeting, held in-person November 8-10 in Basel, Switzerland.
You will have the chance to chat with our experts and demo the universal SOPHiA DDM™ Platform.
More info on our BioData World Congress presence to come.
SOPHiA GENETICS is excited to be a part of the BioData World Congress 2022 annual meeting, held in-person November 8-10 in Basel, Switzerland.
Throughout the congress, our experts will be pleased to meet you at booth #99 to explore how we can help you access high-quality, real-world multimodal data in real-time.
Join us for our panel discussion on Wednesday 09 November at 12:05pm
"Hope or Hype?: The Importance of Multimodal Data Integration to Advance Precision Medicine"
Our panelists will debate the importance of combining a diversity of data modalities for the longitudinal follow-up of patients from diagnosis to treatment to outcomes, to develop a better understanding of the patient journey and to identify patient subpopulations for precision medicine.
The panel discussion will focus on:
Panelists
David Dellamonica, MBA - Head, Digital and Innovation, Oncology Europe & Canada, AstraZeneca
Michael G. Frank, MBA – Digital Ventures Lead, Memorial Sloan Kettering Cancer Center
Jacques Cadranel, MD, Oncologist, Pneumology Service - Sorbonne Université and AP-HP Hôpital Tenon Paris
Philippe Menu, MD, PhD, MBA – Chief Medical Officer, SOPHiA GENETICS
Moderator
Peter Casasanto, MBA – Chief BioPharma Officer, SOPHiA GENETICS
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA GENETICS is excited to be a part of the BIO-Europe 2022 annual meeting, held in-person October 24–26 in Leipzig, Germany.
You will have the chance to chat with our experts at our booth and demo the universal SOPHiA DDM™ Platform.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.